相关实验视频

Updated: May 27, 2025

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Published on: June 5, 2021

感染后的SARS-CoV-2疫苗剂量所提供的保护:上海的一个队列研究

Bo Zheng¹, Bronner P Gonçalves², Pengfei Deng³

¹Department of Epidemiology, School of Public Health, Fudan University, Shanghai, China.

|February 17, 2025

概括

感染后额外的疫苗剂量可以增强对重症急性呼吸综合征冠状病毒2 (SARS-CoV-2) 再感染的保护. 这一发现对于全球COVID-19疫苗接种政策的制定至关重要.

科学领域:

传染性疾病传染性疾病
免疫学免疫学免疫学
公共卫生公共卫生

背景情况:

许多人已经接种了疫苗并感染了SARS-CoV-2.
对公共卫生政策来说,对感染后接种疫苗的量化保护至关重要.
奥米克朗变种的激增凸显了了解混合免疫力的必要性.

研究的目的:

为了估计在最初的Omicron变种感染后,额外的疫苗剂量对再感染的保护作用.
分析先前疫苗接种状态对感染后疫苗有效性的影响.
评估感染后接种疫苗的时间相对于后续的疫苗.

主要方法:

在中国上海进行了以后视的基于人口的队列研究.
利用电子数据库检查SARS-CoV-2感染和疫苗接种史.
采用考克斯模型来计算重新感染的调整危险比率 (aHR).

主要成果:

感染后的疫苗接种显示出对再次感染的显著保护 (aHR 0.82).
有效性因感染前接种的疫苗剂量数量而异.
与第二次Omicron波相比,接种疫苗的时间影响了保护水平 (例如,30天内HR为0.51).

结论:

额外的疫苗剂量可以保护先前接种疫苗和感染的个体免受Omicron变体的再感染.
研究结果支持将感染后疫苗接种纳入COVID-19战略.
结果为中国和全世界的疫苗政策制定提供了宝贵的见解.

关键词:

在 COVID-19 疫情中,这种Omicron变异是什么?流行病学流行病学全球卫生健康全球卫生健康人类人类人类人类人类人类人类混合免疫的混合免疫力传染病是一种传染性疾病.微生物学的微生物.重新感染的情况.疫苗的有效性疫苗的有效性

更多相关视频

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

相关概念视频

Vaccinations

Vaccinations

Viral Mutations

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...